Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.91 EUR | -4.02% | +3.24% | +75.23% |
05-16 | GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024 | CI |
03-20 | Geneuro SA Announces Appointments of Board of Directors | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+75.23% | 61.36M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- GNRO Stock
- News GeNeuro SA
- GeNeuro Wins Regulatory Nod To Launch Mid-stage Study Of Post-COVID-19 Drug In Switzerland